An Evolution of CARs – Autologous vs Allogeneic Strategies

The goal of this presentation is to provide an overview of Chimeric Antigen Receptors (CAR) and their associated immunotherapy strategies. CARs are genetically engineered receptors that provide specific properties to an immune effector cell. Key discussion will highlight CAR evolution from generation to generation to coincide with our understanding of the immune system and the interplay associated with advancing immunotherapy capabilities. Next, we highlight necessary technical capabilities to develop and characterize CAR therapies, i.e. CRISPR, RCL/RCR virus and associated safety testing, HHV safety (allogeneic), Multiplexing, ddPCR. As research continues to evolve, so do the way CARs are engineered and introduced into the immune system as a tool against various pathologies. CAR-T cells can be engineered to target virtually any tumor-associated antigen and, in general, any other antigen. Some recent strategies incorporate expression of a supplementary cytokines associated with immune cell expansion and activation. The cutting-edge strategies from both an Autologous and Allogeneic CAR therapy perspective will be discussed to provide idea on the "state of the field" and associated research trends. Finally, we discuss the future direction of Molecular BioAnalysis in the CGT space to compliment these CAR/immunotherapy studies.